A clinical investigation with Holter's monitoring of the antiarrhythmic effect of adonisidum.
The authors studied 24 cases of refractory premature beats by giving 0.1 adonisidum twice daily with Holter's monitoring. It was found that adonisidum was effective in 12 cases (P less than 0.001), or 50%. In another 8 patients adonisidum or mexiletine alone were ineffective for premature beats. However, when these patients were treated with both mexiletine and adonisidum, they responded with no exception (P less than 0.001). All 7 cases monitored with one hour Holter recording responded to adonisidum (P less than 0.001). As adonisidum tends to slow the heart rate, it is especially indicated for patients suffering from premature beats with increased heart rate, and should be used with caution in cases with slow heart rate or A-V block.
Chen
S X
SX
Zhang
S H
SH
Zhang
X Z
XZ
Zheng
X J
XJ
Yu
G
G
Huang
M X
MX
Zheng
D S
DS
D000293:Adolescent; D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy* / Q000209:etiology; D009202:Cardiomyopathies / Q000150:complications; D003327:Coronary Disease / Q000150:complications; D004562:Electrocardiography; D005260:Female; D006027:Glycosides / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic
D000889:Anti-Arrhythmia Agents; D006027:Glycosides; C051734:adonisidum